Mapping_NN
of_IN
B-cell_NN
epitopes_NNS
of_IN
the_DT
human_JJ
hepatitis_NN
B_NN
virus_NN
X_NN
protein_NN
._.

The_DT
immune_JJ
response_NN
to_TO
the_DT
X_NN
protein_NN
of_IN
human_JJ
hepatitis_NN
B_NN
virus_NN
-LRB-_-LRB-
HBV_NN
-RRB-_-RRB-
was_VBD
studied_VBN
by_IN
epitope_NN
mapping_NN
by_IN
using_VBG
a_DT
set_NN
of_IN
MS2-HBx_NN
fusion_NN
proteins_NNS
and_CC
synthetic_JJ
peptides_NNS
._.

Antibodies_NNS
in_IN
sera_NN
of_IN
patients_NNS
with_IN
acute_JJ
and_CC
chronic_JJ
HBV_NN
infection_NN
showed_VBD
a_DT
multispecific_JJ
immune_JJ
response_NN
._.

Each_DT
serum_NN
contained_VBN
antibodies_NNS
to_TO
a_DT
different_JJ
set_NN
of_IN
epitopes_NNS
,_,
which_WDT
taken_VBN
together_RB
cover_VBP
most_JJS
of_IN
the_DT
HBx_NN
sequence_NN
._.

Some_DT
of_IN
the_DT
epitopes_NNS
were_VBD
detectable_JJ
only_RB
by_IN
immunoblotting_NN
with_IN
fusion_NN
proteins_NNS
;_:
others_NNS
were_VBD
detectable_JJ
only_RB
by_IN
an_DT
enzyme-linked_JJ
immunosorbent_JJ
assay_NN
-LRB-_-LRB-
ELISA_NN
-RRB-_-RRB-
with_IN
synthetic_JJ
peptides_NNS
._.

The_DT
carboxy-terminal_JJ
half_NN
of_IN
the_DT
HBx_NN
protein_NN
was_VBD
preferentially_RB
recognized_VBN
by_IN
antibodies_NNS
from_IN
patients_NNS
with_IN
chronic_JJ
hepatitis_NN
and_CC
contained_VBD
a_DT
short_JJ
immunodominant_JJ
antigenic_JJ
region_NN
with_IN
at_IN
least_JJS
two_CD
major_JJ
nonoverlapping_JJ
epitopes_NNS
._.

Anti-HBx_JJ
antibody_NN
titers_NNS
as_IN
revealed_VBD
by_IN
peptide_NN
ELISAs_NNS
were_VBD
highest_JJS
and_CC
most_RBS
frequent_JJ
in_IN
patients_NNS
with_IN
chronic_JJ
hepatitis_NN
and_CC
usually_RB
low_JJ
in_IN
acutely_RB
infected_JJ
patients_NNS
and_CC
asymptomatic_JJ
carriers_NNS
._.

The_DT
data_NNS
demonstrate_VBP
a_DT
remarkable_JJ
qualitative_JJ
and_CC
quantitative_JJ
heterogeneity_NN
of_IN
the_DT
humoral_JJ
HBx_NN
immune_JJ
response_NN
which_WDT
can_MD
be_VB
monitored_VBN
by_IN
HBx-specific_JJ
peptide_NN
ELISAs_NNS
._.

Such_JJ
tests_NNS
may_MD
become_VB
useful_JJ
diagnostic_JJ
tools_NNS
._.

